secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001193125-22-070592
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics appoints William Ringo as Chair of Board
---------------------------------------------------------------

- William Ringo appointed Chair of the Board effective March 8, 2022; also joins compensation and nominating committees.
- Mr. Ringo brings 40+ years of pharma/biotech experience including Pfizer SVP, Eli Lilly executive roles, and CEO of Abgenix.
- Received an option to purchase 29,100 shares and RSU awards totaling 18,933 shares; annual retainers of $79,000.
- Press release announcing appointment issued March 9, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522070592/0001193125-22-070592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522070592/d280713d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-070592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer